Meijin Huang1, Jinxin Lin2, Xihu Yu2, Shen Chen3, Liang Kang2, Yanhong Deng4, Jian Zheng5, Yanxin Luo2, Lei Wang2, Ping Lan2, Jianping Wang6. 1. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, People's Republic of China. wjpsysu@163.com. 2. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, People's Republic of China. 3. Department of Gynaecology and Obstetrics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People's Republic of China. 4. Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People's Republic of China. 5. Department of Radiation Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510655, People's Republic of China. 6. Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, People's Republic of China. wjp@mail.sysu.edu.cn.
Abstract
OBJECTIVE: The aim was to evaluate erectile and urinary function of male patients with rectal cancer treated by neoadjuvant (NA) chemoradiotherapy (CRT) or NA chemotherapy only. METHODS: In this prospective randomized trial (ClinicalTrials.gov NCT01211210; "FOWARC"), we included 102 men who received NA therapy for stage II-III rectal cancer between January 2011 and June 2013. Before surgery, patients received either NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54) or NA mFOLFOX6 chemotherapy alone (CS group, n = 48). Erectile and urinary dysfunctions were assessed with the five-item International Index of Erectile Function (IIEF-5) scale and the International Prostatic Symptom Score (IPSS), respectively. Questionnaires were completed at baseline and at 3, 6, and 12 months (t0-t3, respectively) after surgery. RESULTS: At t3, mean IIEF-5 score was significant higher in the CS group (15.3 ± 5.5) than in the RCS group (12.6 ± 5.7; P < 0.05). And score difference was statistically higher in RCS group compared with CS group at t2 and t3, especially t3 (9.3 ± 5.5 vs. 6.1 ± 5.1, P < 0.01). Univariate analysis of the RCS group's IIEF-5 scores associated age, stoma, location, and tumor size to erectile dysfunction. However, mean IPSS scores did not differ between the two groups at any point. CONCLUSIONS: Compared with the CS group, erectile and urinary functions were significantly affected by NA CRT. Age, stoma, tumor location, and tumor size were also correlated with erectile dysfunction in the RCS group.
RCT Entities:
OBJECTIVE: The aim was to evaluate erectile and urinary function of male patients with rectal cancer treated by neoadjuvant (NA) chemoradiotherapy (CRT) or NA chemotherapy only. METHODS: In this prospective randomized trial (ClinicalTrials.gov NCT01211210; "FOWARC"), we included 102 men who received NA therapy for stage II-III rectal cancer between January 2011 and June 2013. Before surgery, patients received either NA mFOLFOX6 chemotherapy with radiation (RCS group, n = 54) or NA mFOLFOX6 chemotherapy alone (CS group, n = 48). Erectile and urinary dysfunctions were assessed with the five-item International Index of Erectile Function (IIEF-5) scale and the International Prostatic Symptom Score (IPSS), respectively. Questionnaires were completed at baseline and at 3, 6, and 12 months (t0-t3, respectively) after surgery. RESULTS: At t3, mean IIEF-5 score was significant higher in the CS group (15.3 ± 5.5) than in the RCS group (12.6 ± 5.7; P < 0.05). And score difference was statistically higher in RCS group compared with CS group at t2 and t3, especially t3 (9.3 ± 5.5 vs. 6.1 ± 5.1, P < 0.01). Univariate analysis of the RCS group's IIEF-5 scores associated age, stoma, location, and tumor size to erectile dysfunction. However, mean IPSS scores did not differ between the two groups at any point. CONCLUSIONS: Compared with the CS group, erectile and urinary functions were significantly affected by NA CRT. Age, stoma, tumor location, and tumor size were also correlated with erectile dysfunction in the RCS group.
Entities:
Keywords:
Erectile function; Neoadjuvant; Radiation; Rectal cancer; Urinary function
Authors: Samantha K Hendren; Brenda I O'Connor; Maria Liu; Tracey Asano; Zane Cohen; Carol J Swallow; Helen M Macrae; Robert Gryfe; Robin S McLeod Journal: Ann Surg Date: 2005-08 Impact factor: 12.969
Authors: Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout Journal: J Clin Oncol Date: 2005-03-20 Impact factor: 44.544
Authors: Kjersti Bruheim; Kjell Magne Tveit; Eva Skovlund; Lise Balteskard; Erik Carlsen; Sophie D Fosså; Marianne G Guren Journal: Acta Oncol Date: 2010-08 Impact factor: 4.089
Authors: R Glynne-Jones; M R Hall; A Lopes; S Pearce; V Goh; S Bosompem; J Bridgewater; I Chau; H Wasan; B Moran; L Melcher; N P West; P Quirke; W-L Wong; S Beare; N Hava; M Duggan; M Harrison Journal: Heliyon Date: 2018-09-22
Authors: Gyu Sang Yoo; Hee Chul Park; Jeong Il Yu; Doo Ho Choi; Won Kyung Cho; Young Suk Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Woo Yong Lee; Hee Cheol Kim; Seong Hyeon Yun; Yong Beom Cho; Yoon Ah Park; Kyoung Doo Song; Seok-Hyung Kim; Sang Yun Ha Journal: Cancer Res Treat Date: 2019-09-25 Impact factor: 4.679